|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:sorafenib
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XE05
|
|
gptkbp:brand
|
gptkb:Nexavar
|
|
gptkbp:CASNumber
|
284461-73-0
|
|
gptkbp:chemicalFormula
|
C21H16ClF3N4O3
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
25-48 hours
|
|
gptkbp:genericName
|
gptkb:sorafenib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nexavar (sorafenib)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bayer
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
inhibits multiple kinases
|
|
gptkbp:metabolism
|
liver (CYP3A4, UGT1A9)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
99.5%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
hypertension
rash
hand-foot skin reaction
|
|
gptkbp:usedFor
|
hepatocellular carcinoma
renal cell carcinoma
differentiated thyroid carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|